|
SMT202300208T1
(it)
*
|
2012-10-23 |
2023-09-06 |
Synaffix Bv |
Anticorpo modificato, coniugato di anticorpo e processo per la preparazione degli stessi
|
|
CA2902872A1
(en)
|
2013-03-15 |
2014-09-18 |
Regeneron Pharmaceuticals, Inc. |
Biologically active molecules, conjugates thereof, and therapeutic uses
|
|
WO2014177771A1
(en)
*
|
2013-05-02 |
2014-11-06 |
Glykos Finland Oy |
Conjugates of a glycoprotein or a glycan with a toxic payload
|
|
MX373528B
(es)
|
2013-08-26 |
2020-04-21 |
Regeneron Pharma |
Composiciones farmacéuticas que contienen diasterómeros macrólidos, métodos para su síntesis y usos terapéuticos.
|
|
WO2015057063A1
(en)
*
|
2013-10-14 |
2015-04-23 |
Synaffix B.V. |
Modified glycoprotein, protein-conjugate and process for the preparation thereof
|
|
US9987373B2
(en)
|
2013-10-14 |
2018-06-05 |
Synaffix B.V. |
Modified glycoprotein, protein-conjugate and process for the preparation thereof
|
|
WO2015057066A1
(en)
*
|
2013-10-14 |
2015-04-23 |
Synaffix B.V. |
Glycoengineered antibody, antibody-conjugate and methods for their preparation
|
|
CN105764491A
(zh)
|
2013-12-09 |
2016-07-13 |
度瑞公司 |
药物活性剂复合物、聚合物复合物，以及包括其的组合物和方法
|
|
EP3097079B1
(en)
|
2014-01-24 |
2021-05-12 |
SynAffix B.V. |
Process for the cycloaddition of a hetero(aryl) 1,3-dipole compound with a (hetero)cycloalkyne
|
|
WO2015112016A1
(en)
*
|
2014-01-24 |
2015-07-30 |
Synaffix B.V. |
Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
|
|
US10905678B2
(en)
|
2014-04-08 |
2021-02-02 |
University Of Georgia Research Foundation, Inc. |
Site-specific antibody-drug glycoconjugates and methods
|
|
WO2016001485A1
(en)
|
2014-06-30 |
2016-01-07 |
Glykos Finland Oy |
Saccharide derivative of a toxic payload and antibody conjugates thereof
|
|
EP2974744A1
(en)
|
2014-07-16 |
2016-01-20 |
Stichting Katholieke Universiteit |
Strain-promoted oxidation controlled cycloaddition with high reaction rate
|
|
WO2016022027A1
(en)
|
2014-08-04 |
2016-02-11 |
Synaffix B.V. |
Process for the modification of a glycoprotein using a βeta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof
|
|
CN107106701B
(zh)
*
|
2014-10-03 |
2020-11-06 |
西纳福克斯股份有限公司 |
磺酰胺接头、其缀合物及制备方法
|
|
CN107406463A
(zh)
*
|
2014-12-04 |
2017-11-28 |
细胞基因公司 |
生物分子共轭物
|
|
US20170369525A1
(en)
*
|
2014-12-31 |
2017-12-28 |
Development Center For Biotechnology |
Site-specific conjugation through glycoproteins linkage and method thereof
|
|
US11559581B2
(en)
*
|
2015-01-09 |
2023-01-24 |
Oxford University Innovation Limited |
Antibody conjugates and methods of making the antibody conjugates
|
|
BR112017020149A8
(pt)
|
2015-03-27 |
2023-05-02 |
Regeneron Pharma |
Derivados de maitansinoide, conjugados dos mesmos e métodos de uso
|
|
ES2659816T3
(es)
|
2015-04-23 |
2018-03-19 |
Synaffix B.V. |
Proceso para la modificación de una glucoproteína utilizando una glucosiltransferasa que es o que deriva de una (1,4)-n-acetilgalactosaminiltransferasa
|
|
US10988508B2
(en)
*
|
2015-04-24 |
2021-04-27 |
University Of Delaware |
Synthetic N-acetyl-muramic acid derivatives and uses thereof
|
|
CN107849131A
(zh)
|
2015-07-06 |
2018-03-27 |
瑞泽恩制药公司 |
多特异性抗原结合分子及其用途
|
|
WO2017032888A1
(en)
*
|
2015-08-26 |
2017-03-02 |
Vib Vzw |
Means and methods for monitoring inflammation
|
|
EP3371200A4
(en)
*
|
2015-10-07 |
2020-04-29 |
The Board of Trustees of the University of Illinois |
METABOLIC SUGAR PRECURSORS ACTIVABLE BY A TRIGGER FOR THE MARKING AND SELECTIVE TARGETING OF CANCER
|
|
EP3165237B1
(en)
|
2015-11-03 |
2018-12-19 |
Industrial Technology Research Institute |
Antibody-drug conjugate (adc) and method for forming the same
|
|
MA43416A
(fr)
|
2015-12-11 |
2018-10-17 |
Regeneron Pharma |
Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
|
|
EA039072B9
(ru)
*
|
2016-01-25 |
2022-02-04 |
Регенерон Фармасьютикалз, Инк. |
Производные майтанзиноида, их конъюгаты и способы применения
|
|
CN108495653A
(zh)
*
|
2016-01-27 |
2018-09-04 |
免疫医疗有限责任公司 |
用于制备具有定义的糖基化模式抗体的方法
|
|
JP2017197512A
(ja)
*
|
2016-02-08 |
2017-11-02 |
シンアフィックス ビー．ブイ． |
Ｃｄ３０腫瘍を標的化するための改善された治療指数を有する新規な抗体−コンジュゲート及び抗体−コンジュゲートの治療指数を改善するための方法
|
|
WO2017137456A1
(en)
|
2016-02-08 |
2017-08-17 |
Synaffix B.V. |
Bioconjugates containing sulfamide linkers for use in treatment
|
|
US11590239B2
(en)
*
|
2016-02-08 |
2023-02-28 |
Synaffix B.V. |
Antibody-conjugates with improved therapeutic index for targeting CD30 tumours and method for improving therapeutic index of antibody-conjugates
|
|
WO2017137423A1
(en)
|
2016-02-08 |
2017-08-17 |
Synaffix B.V. |
Improved sulfamide linkers for use in bioconjugates
|
|
EP3414328B1
(en)
|
2016-02-08 |
2024-01-10 |
Synaffix B.V. |
Enzymes for trimming of glycoproteins
|
|
EP3413916A1
(en)
|
2016-02-08 |
2018-12-19 |
Synaffix B.V. |
Antibody-conjugates with improved therapeutic index for targeting cd30 tumours and method for improving therapeutic index of antibody-conjugates
|
|
JP2017200902A
(ja)
*
|
2016-02-08 |
2017-11-09 |
シンアフィックス ビー．ブイ． |
Ｈｅｒ２腫瘍を標的化するための改善された治療指数を有する新規な抗体−コンジュゲート及び抗体−コンジュゲートの治療指数を改善するための方法
|
|
WO2017137457A1
(en)
|
2016-02-08 |
2017-08-17 |
Synaffix B.V. |
Antibody-conjugates with improved therapeutic index for targeting cd30 tumours and method for improving therapeutic index of antibody-conjugates
|
|
PE20181953A1
(es)
|
2016-03-02 |
2018-12-17 |
Eisai Randd Man Co Ltd |
Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
|
|
EP3448891A1
(en)
|
2016-04-28 |
2019-03-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of making multispecific antigen-binding molecules
|
|
WO2017191817A1
(ja)
*
|
2016-05-02 |
2017-11-09 |
味の素株式会社 |
アジド基含有Ｆｃタンパク質
|
|
WO2017218891A1
(en)
*
|
2016-06-17 |
2017-12-21 |
Life Technologies Corporation |
Site-specific crosslinking of antibodies
|
|
EP3475291B1
(en)
|
2016-06-28 |
2025-10-01 |
Ventana Medical Systems, Inc. |
Application of click chemistry for signal amplification in ihc and ish assays
|
|
EP3478324A1
(en)
|
2016-07-01 |
2019-05-08 |
GlaxoSmithKline Intellectual Property (No.2) Limited |
Antibody-drug conjugates and therapeutic methods using the same
|
|
CN109462989A
(zh)
*
|
2016-07-01 |
2019-03-12 |
第三共株式会社 |
Hanp-含fc分子缀合物
|
|
MX2019003325A
(es)
*
|
2016-09-23 |
2019-08-05 |
Regeneron Pharma |
Anticuerpos anti-steap2, conjugados anticuerpo-farmaco, y moleculas de fijacion al antigeno biespecificas que se fijan a steap2 y cd3, y usos de estos.
|
|
US10738338B2
(en)
|
2016-10-18 |
2020-08-11 |
The Research Foundation for the State University |
Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
|
|
MX394528B
(es)
|
2016-11-08 |
2025-03-24 |
Regeneron Pharma |
Esteroides y conjugados de proteinas de los mismos.
|
|
TWI807423B
(zh)
*
|
2016-11-14 |
2023-07-01 |
醣基生醫股份有限公司 |
抗體藥物複合體
|
|
TWI782930B
(zh)
|
2016-11-16 |
2022-11-11 |
美商再生元醫藥公司 |
抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
|
|
CN110121365A
(zh)
|
2016-12-29 |
2019-08-13 |
财团法人生物技术开发中心 |
制备糖蛋白-药物偶联物的方法
|
|
US20200023071A1
(en)
|
2017-02-06 |
2020-01-23 |
Innate Pharma |
Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
|
|
JP2020507584A
(ja)
|
2017-02-10 |
2020-03-12 |
ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ |
癌選択的標識および標的化のためのトリガー活性化可能な糖コンジュゲート
|
|
CA3062238A1
(en)
|
2017-05-11 |
2018-11-15 |
Vib Vzw |
Glycosylation of variable immunoglobulin domains
|
|
AU2018269568B2
(en)
|
2017-05-18 |
2022-03-24 |
Regeneron Pharmaceuticals, Inc. |
Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
|
|
KR20250008984A
(ko)
|
2017-05-18 |
2025-01-16 |
리제너론 파마슈티칼스 인코포레이티드 |
사이클로덱스트린 단백질 약물 접합체
|
|
EP3635009A1
(en)
|
2017-06-07 |
2020-04-15 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for internalizing enzymes
|
|
US11236059B2
(en)
|
2017-08-09 |
2022-02-01 |
Helmholtz-Zentrum Fuer Infektionsforschung Gmbh |
Targeted cytotoxic ratjadone derivatives and conjugates thereof
|
|
ES2803350T3
(es)
*
|
2017-08-11 |
2021-01-26 |
Life Science Inkubator Sachsen Gmbh & Co Kg |
Novedosos conjugados de anticuerpos adecuados para su uso en inmunoensayos aislados de desplazamiento de la inactivación de la fluorescencia
|
|
JP7273716B2
(ja)
*
|
2017-09-29 |
2023-05-15 |
第一三共株式会社 |
抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
|
|
SG11202004151YA
(en)
|
2017-11-07 |
2020-06-29 |
Regeneron Pharma |
Hydrophilic linkers for antibody drug conjugates
|
|
JP7165193B2
(ja)
|
2017-11-27 |
2022-11-02 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
ヒト組織因子を標的とするヒト化抗体
|
|
WO2019110725A1
(en)
|
2017-12-06 |
2019-06-13 |
Synaffix B.V. |
Enediyne conjugates
|
|
US11548908B2
(en)
|
2017-12-29 |
2023-01-10 |
Glycomimetics, Inc. |
Heterobifunctional inhibitors of E-selectin and galectin-3
|
|
CA3086926A1
(en)
|
2018-01-08 |
2019-07-11 |
Regeneron Pharmaceuticals, Inc. |
Steroids and antibody-conjugates thereof
|
|
MX2020011487A
(es)
|
2018-04-30 |
2020-12-07 |
Regeneron Pharma |
Anticuerpos y moleculas biespecificas de union al antigeno que se unen a her2 y/o aplp2, conjugados y usos de estos.
|
|
SG11202010909RA
(en)
|
2018-05-09 |
2020-12-30 |
Regeneron Pharma |
Anti-msr1 antibodies and methods of use thereof
|
|
EP3793591A1
(en)
|
2018-05-17 |
2021-03-24 |
Regeneron Pharmaceuticals, Inc. |
Anti-cd63 antibodies, conjugates, and uses thereof
|
|
JP2019206491A
(ja)
*
|
2018-05-29 |
2019-12-05 |
国立研究開発法人理化学研究所 |
乳がんまたは胃がんの治療のための抗体−薬物複合体
|
|
US12103978B2
(en)
|
2018-06-15 |
2024-10-01 |
Shanghai Miracogen Inc. |
Methods and materials for treating cancer
|
|
KR20210081324A
(ko)
|
2018-08-02 |
2021-07-01 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도
|
|
SG11202100934PA
(en)
|
2018-08-02 |
2021-02-25 |
Dyne Therapeutics Inc |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US11168141B2
(en)
|
2018-08-02 |
2021-11-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US11911484B2
(en)
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
US12370264B1
(en)
|
2018-08-02 |
2025-07-29 |
Dyne Therapeutics, Inc. |
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
|
|
JP7576542B2
(ja)
*
|
2018-08-02 |
2024-10-31 |
ダイン セラピューティクス，インコーポレーテッド |
筋標的化複合体およびそれらの使用
|
|
JP7705793B2
(ja)
*
|
2018-08-02 |
2025-07-10 |
ダイン セラピューティクス，インコーポレーテッド |
筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用
|
|
CN113260384A
(zh)
|
2018-11-05 |
2021-08-13 |
西纳福克斯股份有限公司 |
用于靶向表达trop-2的肿瘤的抗体缀合物
|
|
BR112021009673A2
(pt)
|
2018-11-20 |
2021-12-14 |
Regeneron Pharma |
Derivados de bis-octa-hidrofenantreno carboxamida e conjugados de proteínas dos mesmos para uso como agonistas de lxr
|
|
MA53765B2
(fr)
|
2018-12-21 |
2025-04-30 |
Regeneron Pharmaceuticals, Inc. |
Tubulysines et conjugués tubulysines-protéines
|
|
AU2019403404B2
(en)
|
2018-12-21 |
2025-05-29 |
Regeneron Pharmaceuticals, Inc. |
Rifamycin analogs and antibody-drug conjugates thereof
|
|
US11845771B2
(en)
|
2018-12-27 |
2023-12-19 |
Glycomimetics, Inc. |
Heterobifunctional inhibitors of E-selectin and galectin-3
|
|
CN118373810A
(zh)
|
2018-12-27 |
2024-07-23 |
糖模拟物有限公司 |
抑制c-糖苷的半乳凝素-3
|
|
CA3125998A1
(en)
|
2019-01-08 |
2020-07-16 |
Regeneron Pharmaceuticals, Inc. |
Traceless linkers and protein-conjugates thereof
|
|
GB201901608D0
(en)
|
2019-02-06 |
2019-03-27 |
Vib Vzw |
Vaccine adjuvant conjugates
|
|
CN113727757A
(zh)
|
2019-02-21 |
2021-11-30 |
瑞泽恩制药公司 |
使用结合met的抗-met抗体和双特异性抗原结合分子治疗眼癌的方法
|
|
EP3950061A4
(en)
*
|
2019-03-25 |
2022-11-16 |
Daiichi Sankyo Company, Limited |
ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
|
|
SG11202109860VA
(en)
*
|
2019-03-25 |
2021-10-28 |
Daiichi Sankyo Co Ltd |
Anti-her2 antibody-pyrrolobenzodiazepine derivative conjugate
|
|
BR112021017350A2
(pt)
*
|
2019-03-27 |
2021-11-16 |
Daiichi Sankyo Co Ltd |
Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
|
|
WO2020245229A1
(en)
|
2019-06-03 |
2020-12-10 |
Synaffix B.V. |
Acetal-based cleavable linkers
|
|
WO2021055350A1
(en)
|
2019-09-16 |
2021-03-25 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled met binding proteins for immuno-pet imaging
|
|
US11814428B2
(en)
|
2019-09-19 |
2023-11-14 |
Regeneron Pharmaceuticals, Inc. |
Anti-PTCRA antibody-drug conjugates and uses thereof
|
|
AU2019341067B2
(en)
*
|
2019-09-29 |
2021-08-05 |
Mabplex International Co., Ltd. |
Method for producing antibody-drug conjugate intermediate by addition of acid and use thereof
|
|
GB201917388D0
(en)
*
|
2019-11-28 |
2020-01-15 |
Cambridge Entpr Ltd |
Novel linker compounds
|
|
GB201918279D0
(en)
|
2019-12-12 |
2020-01-29 |
Vib Vzw |
Glycosylated single chain immunoglobulin domains
|
|
CA3163833A1
(en)
*
|
2020-01-09 |
2021-07-15 |
Timothy B. Lowinger |
Site specific antibody-drug conjugates with peptide-containing linkers
|
|
CN115768483A
(zh)
|
2020-01-13 |
2023-03-07 |
西纳福克斯股份有限公司 |
抗体与免疫细胞衔接器的缀合物
|
|
WO2021144314A1
(en)
|
2020-01-13 |
2021-07-22 |
Synaffix B.V. |
Via cycloaddition bilaterally functionalized antibodies
|
|
JP2023511857A
(ja)
|
2020-01-13 |
2023-03-23 |
シンアフィックス ビー．ブイ． |
付加環化を介して両側官能化された抗体
|
|
KR20220131266A
(ko)
|
2020-01-24 |
2022-09-27 |
리제너론 파마슈티칼스 인코포레이티드 |
단백질-항바이러스 화합물 접합체
|
|
CA3166619A1
(en)
|
2020-02-28 |
2021-09-02 |
Julian Andreev |
Bispecific antigen binding molecules that bind her2, and methods of use thereof
|
|
CA3179154A1
(en)
|
2020-04-16 |
2021-10-21 |
Regeneron Pharmaceuticals, Inc. |
Diels-alder conjugation methods
|
|
EP4149548A4
(en)
|
2020-05-13 |
2024-05-08 |
Disc Medicine, Inc. |
ANTI-HEMOJUVELIN ANTIBODIES (HJV) FOR THE TREATMENT OF MYELOFIBROSIS
|
|
KR20230015348A
(ko)
|
2020-05-25 |
2023-01-31 |
고에키 자이단 호징 고베 이료 산교 도시 스이신 기코 |
Th2 개재성 질환을 치료 또는 예방하기 위한 PD-1 작용제 함유 의약 조성물
|
|
CN111560078A
(zh)
*
|
2020-06-19 |
2020-08-21 |
联宁（苏州）生物制药有限公司 |
具有马来酰亚胺接头的双臂中间体及其合成方法
|
|
MA58646A1
(fr)
|
2020-06-24 |
2023-08-31 |
Regeneron Pharma |
Tubulysines et conjugués tubulysines-protéines
|
|
EP4172141A1
(en)
|
2020-06-26 |
2023-05-03 |
Synaffix B.V. |
Methods for the preparation of linker payload constructs
|
|
BR112023000489A2
(pt)
|
2020-07-13 |
2023-03-28 |
Regeneron Pharma |
Análogos de camptotecina conjugados a um resíduo de glutamina em uma proteína, e seu uso
|
|
NL2026400B1
(en)
|
2020-09-02 |
2022-05-04 |
Synaffix Bv |
Methods for the preparation of bioconjugates
|
|
AU2021339892A1
(en)
|
2020-09-14 |
2023-04-27 |
Regeneron Pharmaceuticals, Inc. |
Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof
|
|
WO2022058395A1
(en)
|
2020-09-15 |
2022-03-24 |
Synaffix B.V. |
Antibody-exatecan conjugates
|
|
WO2022079211A1
(en)
|
2020-10-16 |
2022-04-21 |
Adc Therapeutics Sa |
Glycoconjugates
|
|
US20240042053A1
(en)
|
2020-10-16 |
2024-02-08 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
|
CA3190569A1
(en)
|
2020-10-22 |
2022-04-28 |
Christopher Daly |
Anti-fgfr2 antibodies and methods of use thereof
|
|
NL2026947B1
(en)
|
2020-11-20 |
2022-07-01 |
Synaffix Bv |
Tyrosine-based antibody conjugates
|
|
WO2022136705A1
(en)
|
2020-12-24 |
2022-06-30 |
Synaffix B.V. |
Glycan-conjugated antibodies binding to fc-gamma receptor
|
|
CA3202832A1
(en)
|
2020-12-31 |
2022-07-07 |
Romesh R. Subramanian |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US20250262314A1
(en)
|
2021-02-08 |
2025-08-21 |
Synaffix B.V. |
Multifunctional antibodies
|
|
AU2022253902A1
(en)
|
2021-04-10 |
2023-11-02 |
Genmab A/S |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
TW202308699A
(zh)
|
2021-04-23 |
2023-03-01 |
美商普方生物製藥美國公司 |
Ｃｄ７０結合劑、其結合物及其使用方法
|
|
AU2022309028A1
(en)
|
2021-07-09 |
2024-01-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations for treating dystrophinopathies
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
US11648318B2
(en)
|
2021-07-09 |
2023-05-16 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor (TFR) antibody and uses thereof
|
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US11771776B2
(en)
|
2021-07-09 |
2023-10-03 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US11638761B2
(en)
|
2021-07-09 |
2023-05-02 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
|
|
US20250041433A1
(en)
|
2021-07-28 |
2025-02-06 |
Regeneron Pharmaceuticals, Inc. |
Protein-antiviral compound conjugates
|
|
CN118119633A
(zh)
*
|
2021-10-20 |
2024-05-31 |
岩唐生物科技(杭州)有限责任公司 |
位点特异性糖蛋白偶联物及其制备方法
|
|
KR102782629B1
(ko)
*
|
2021-11-12 |
2025-03-19 |
닥터아이앤비(주) |
생산 시간을 단축하고 안정성이 개선된 의약품 제조방법
|
|
WO2023091968A1
(en)
|
2021-11-17 |
2023-05-25 |
Disc Medicine, Inc. |
Methods for treating anemia of kidney disease
|
|
US20230414775A1
(en)
|
2021-12-29 |
2023-12-28 |
Regeneron Pharmaceuticals, Inc. |
Tubulysins and protein-tubulysin conjugates
|
|
JP2025502147A
(ja)
|
2022-01-12 |
2025-01-24 |
リジェネロン ファーマシューティカルズ，インク． |
タンパク質中のグルタミン残基にコンジュゲートしたカンプトテシンアナログおよびその使用
|
|
JP2025503700A
(ja)
|
2022-01-14 |
2025-02-04 |
レジェネロン ファーマシューティカルズ， インコーポレイテッド |
ベルカリンａ誘導体及びその抗体薬物複合体
|
|
WO2023141855A1
(en)
*
|
2022-01-27 |
2023-08-03 |
Glyco-Therapy Biotechnology Co., Ltd. |
Protein conjugates with multiple payloads and methods for making the same
|
|
CA3244590A1
(en)
*
|
2022-02-22 |
2023-08-31 |
Adc Therapeutics Sa |
CONJUGATION PROCESS INVOLVING A TRANSGLUTAMINASE AT THE FC REGION COMPRISING A TRUNCATED N-GLYCAN
|
|
EP4489855A1
(en)
|
2022-03-11 |
2025-01-15 |
Regeneron Pharmaceuticals, Inc. |
Anti-glp1r antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof
|
|
IL315207A
(en)
|
2022-03-23 |
2024-10-01 |
Synaffix Bv |
Antibody-conjugates for targeting of tumours expressing trop-2
|
|
US20250205353A1
(en)
|
2022-03-23 |
2025-06-26 |
Synaffix B.V. |
Antibody-conjugates for targeting of tumours expressing nectin-4
|
|
MX2024011519A
(es)
|
2022-03-23 |
2024-09-24 |
Synaffix Bv |
Conjugados de anticuerpos para el direccionamiento contra tumores que expresan el antigeno carcinoembrionario.
|
|
CA3254479A1
(en)
|
2022-03-23 |
2023-09-28 |
Synaffix B.V. |
ANTIBODY CONJUGATIONS FOR TARGETTING PTK7-EXPRESSING TUMORS
|
|
IL316143A
(en)
|
2022-04-15 |
2024-12-01 |
Dyne Therapeutics Inc |
Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
|
|
EP4285934A1
(en)
|
2022-05-30 |
2023-12-06 |
CER Groupe |
Modified trimannose-oligosacharides, bisected n-glycans comprising said trimannose core and method for obtaining them
|
|
AU2023310999A1
(en)
|
2022-07-21 |
2025-01-23 |
Firefly Bio, Inc. |
Glucocorticoid receptor agonists and conjugates thereof
|
|
JP2025526869A
(ja)
|
2022-08-15 |
2025-08-15 |
シンアフィックス ビー．ブイ． |
アントラサイクリン及びそのコンジュゲート
|
|
EP4344707A1
(en)
|
2022-09-29 |
2024-04-03 |
Emergence Therapeutics AG |
New anti-nectin-4 antibody drug conjugates
|
|
EP4626553A2
(en)
|
2022-11-30 |
2025-10-08 |
Regeneron Pharmaceuticals, Inc. |
Tlr7 agonists and antibody-drug-conjugates thereof
|
|
WO2024121123A1
(en)
|
2022-12-06 |
2024-06-13 |
Synaffix B.V. |
Synthesis of endo-bicyclononene
|
|
AU2023407365A1
(en)
|
2022-12-21 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof
|
|
CN120456931A
(zh)
*
|
2022-12-22 |
2025-08-08 |
詹森药业有限公司 |
制备抗体-多核苷酸缀合物的方法
|
|
EP4389152A1
(en)
|
2022-12-23 |
2024-06-26 |
Synaffix B.V. |
Conjugates of pbd prodrugs
|
|
WO2024150074A2
(en)
|
2023-01-13 |
2024-07-18 |
Takeda Pharmaceutical Company Limited |
Coronavirus antibodies and therapeutic uses thereof
|
|
TW202434309A
(zh)
|
2023-01-19 |
2024-09-01 |
大陸商上海盛迪醫藥有限公司 |
酪胺酸酶介導的蛋白定點偶聯及其應用
|
|
EP4410313A1
(en)
|
2023-01-31 |
2024-08-07 |
Synaffix B.V. |
Homogeneous antibody-conjugates with high payload loading
|
|
CN121001751A
(zh)
|
2023-02-09 |
2025-11-21 |
里珍纳龙药品有限公司 |
借助逆电子需求狄尔斯-阿尔德反应的抗体-药物缀合物
|
|
WO2024182714A1
(en)
|
2023-03-02 |
2024-09-06 |
Alloy Therapeutics, Inc. |
Anti-cd22 antibodies and uses thereof
|
|
WO2024199432A1
(en)
*
|
2023-03-30 |
2024-10-03 |
Genequantum Healthcare (Suzhou) Co., Ltd. |
Site-speicfic orthogonal bioconjugate modality and application thereof
|
|
WO2024199442A1
(en)
*
|
2023-03-30 |
2024-10-03 |
Genequantum Healthcare (Suzhou) Co., Ltd. |
Disaccharide linker, linker-payload containing the same and glycan chain-remodeled antibody-drug conjugate, preparation method and uses thereof
|
|
EP4450093A1
(en)
|
2023-04-17 |
2024-10-23 |
Synaffix B.V. |
Cleavable immune cell engagers
|
|
EP4450489A1
(en)
|
2023-04-18 |
2024-10-23 |
Synaffix B.V. |
Stable 4-isoxazoline conjugates
|
|
WO2024218164A1
(en)
|
2023-04-17 |
2024-10-24 |
Synaffix B.V. |
Stable 4-isoxazoline conjugates
|
|
WO2024229105A1
(en)
|
2023-05-02 |
2024-11-07 |
Regeneron Pharmaceuticals, Inc. |
Anti-human m-cadherin (cdh15) antibodies, conjugates, and uses thereof for delivery of genetic payloads to muscle cells
|
|
WO2024231447A1
(en)
|
2023-05-08 |
2024-11-14 |
Sanofi |
Glycosylation of immunoglobulin single variable domains
|
|
WO2024251826A1
(en)
|
2023-06-05 |
2024-12-12 |
Vib Vzw |
Glyco-engineered antibody-drug-conjugates comprising an oxime linker
|
|
WO2025011557A1
(en)
*
|
2023-07-10 |
2025-01-16 |
Surio Therapeutics Co. Ltd |
Functionalized auristatins, pharmaceutical compositions, and therapeutic applications
|
|
WO2025014533A1
(en)
|
2023-07-10 |
2025-01-16 |
Regeneron Pharmaceuticals, Inc. |
Anti-human cacng1 antibody-drug conjugates and uses thereof
|
|
WO2025024334A1
(en)
|
2023-07-21 |
2025-01-30 |
Marrow Therapeutics, Inc. |
Hematopoietic cell targeting conjugates and related methods
|
|
WO2025027529A1
(en)
|
2023-07-31 |
2025-02-06 |
Advesya |
Anti-il-1rap antibody drug conjugates and methods of use thereof
|
|
AR133955A1
(es)
|
2023-09-26 |
2025-11-19 |
Profoundbio Us Co |
Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
|
|
EP4541376A1
(en)
|
2023-10-17 |
2025-04-23 |
ADC Therapeutics SA |
Antibody-drug conjugates
|
|
WO2025096921A1
(en)
|
2023-11-03 |
2025-05-08 |
Regeneron Pharmaceuticals, Inc. |
Peptide acids as a glp1r agonist and antibody-drug conjugates thereof
|
|
WO2025117727A1
(en)
|
2023-11-29 |
2025-06-05 |
Regeneron Pharmaceuticals, Inc. |
Analogs of quinoxaline/quinoline cytotoxins, linker- payloads, protein-drug conjugates, and uses thereof
|
|
WO2025126157A1
(en)
|
2023-12-15 |
2025-06-19 |
Advesya |
Anti-il-1rap binding domains and antibody-drug conjugates thereof
|
|
EP4574174A1
(en)
|
2023-12-19 |
2025-06-25 |
Jack Elands |
Novel antibody-drug conjugates comprising an anti-(tcr)-cd3-complex binding antibody
|
|
WO2025149667A1
(en)
|
2024-01-12 |
2025-07-17 |
Pheon Therapeutics Ltd |
Antibody drug conjugates and uses thereof
|
|
WO2025163120A1
(en)
|
2024-02-01 |
2025-08-07 |
Adcytherix Sas |
ANTIBODY-DRUG CONJUGATES COMPRISING AN ANTI-INTEGRIN ΑVβ6 BINDING ANTIBODY
|
|
WO2025172468A1
(en)
|
2024-02-13 |
2025-08-21 |
Synaffix B.V. |
Method for producing azido-sugars and compounds obtained thereby
|
|
WO2025181219A1
(en)
|
2024-02-29 |
2025-09-04 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|
|
WO2025238253A1
(en)
|
2024-05-16 |
2025-11-20 |
Synaffix B.V. |
Antibody-oligonucleotide conjugates
|